Nasus Pharma Ltd
Research Nasus Pharma Ltd (NSRX) on Bullrun: market cap USD 41.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNSRX
- ExchangeNYSE MKT
- CountryIsrael
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Market capUSD 41.10M
- Financial periodQ2 2026
Valuation Snapshot
latest market cap is USD 41.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.24B | -USD 5.86M | -USD 4.93M | n/a | -0.72 | USD 1.24M | USD 118.00K | USD 2.77M |
| FY2024 | USD 0 | -USD 1.53M | -USD 665.00K | n/a | -0.22 | USD 284.00K | USD 1.80M | -USD 3.21M |
| FY2023 | USD 0 | -USD 1.05M | -USD 1.03M | n/a | -0.2 | USD 193.00K | USD 2.46M | -USD 3.80M |
| FY2022 | USD 0 | -USD 1.71M | -USD 1.21M | n/a | -0.24 | USD 154.00K | USD 1.57M | -USD 2.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 41.10M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 82.49M | n/a | n/a | n/a |
About Nasus Pharma Ltd
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nasus Pharma Ltd's market cap?
Nasus Pharma Ltd's market capitalization is USD 41.10M.
What does Nasus Pharma Ltd do?
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.